Evidence map›Paper›PMID 42414254›Full record

ArticleCell death & disease2026

Lactate-induced H3K4me3 histone mark promotes PLOD1-driven prostate cancer invasion.

Marta Iozzo, Luigi Ippolito, Erica Pranzini, Simone Romagnoli, Giulia Gangarossa, Caterina Grillo, Sara Roccabianca, Giada Sandrini, Matteo Benelli, Giuseppina Comito and 2 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta IozzoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. marta.iozzo@unifi.it.ORCID http://orcid.org/0000-0003-2533-6646
Luigi IppolitoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Erica PranziniDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0002-1668-2777
Simone RomagnoliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Giulia GangarossaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Caterina GrilloDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Sara RoccabiancaDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Giada SandriniDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matteo BenelliDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Giuseppina ComitoDepartment of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Elisa Giannoni *Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.ORCID http://orcid.org/0000-0001-7136-1098
Paola Chiarugi *Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. paola.chiarugi@unifi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) progression is strongly influenced by the metabolites available in the tumor microenvironment (TME), including lactic acid (LA), which is actively imported by PCa cells to boost mitochondrial metabolism and drive de novo collagen synthesis, sustaining increased malignancy. LA exploitation promotes the unbalance of tricarboxylic acid (TCA) cycle intermediates, particularly succinate and fumarate, well-known epigenetic modifiers for histone (de)methylation. Here, we show that the LA-induced increase in succinate levels affects the activating H3K4me3 methylation mark in PCa cells, promoting a pro-invasive phenotype. Notably, pharmacological targeting of H3K4me3 using OICR-9429 reduces LA-enhanced PCa cell invasiveness. Moreover, LA-induced H3K4me3 enrichment regulates the expression of procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 1 (PLOD1), a key enzyme involved in collagen maturation. Genetic impairment of PLOD1 reduces the LA-driven invasive potential of PCa cells, thereby highlighting PLOD1 as a crucial epigenetically regulated mediator of tumor invasion. Overall, our findings uncover a novel LA-fuelled metabolic-epigenetic axis that promotes the H3K4me3-mediated PLOD1 upregulation, consequently fostering PCa aggressiveness and unveiling a potential therapeutic vulnerability.

Indexed as

HistonesLactic AcidProcollagen-Lysine, 2-Oxoglutarate 5-DioxygenaseProstatic NeoplasmsAnimalsCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansLysineMaleMethylationNeoplasm InvasivenessHistonesLactic AcidLysineProcollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase

Identifiers

PMID42414254
PMCPMC13620169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.